Polymer blends for controlled release coatings

Siepmann, Florence; Siepmann, Juergen; Walther, Mathias; MacRae, Ross J.; Bodmeier, Roland

doi:10.1016/j.jconrel.2007.09.012

Cited by 278 publications

(155 citation statements)

References 69 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…30 However, the system based on polymer blend is more complex than that of single polymer; for example, the polymer mixture can be incompatible, and aqueous polymer dispersions might flocculate during long-term storage. For this reason, more attention has to be paid when using this type of formulation.…”

Section: Biodegradable Materialsmentioning

confidence: 99%

Recent advances in materials for extended-release antibiotic delivery system

et al. 2011

View full text Add to dashboard Cite

To maintain antimicrobial activity, frequent administration of conventional formulations of many antibiotics with short half-life is necessary. Otherwise, concentration under MIC occurs frequently in the course of anti-infective treatment, which induces antibiotic resistance. By maintaining a constant plasma drug concentration over MIC for a prolonged period, extended-release dosage forms maximize the therapeutic effect of antibiotics while minimizing antibiotic resistance. Another undoubted advantage of extended-release formulation is improved patient compliance. For better release properties, many materials have been introduced into the matrix and coating extended-release system in the past few years. Materials that have been widely used in industry are hydrophilic matrix materials such as hydroxypropylmethylcellulose. The excellent biocompatibility and extensive laboratory studies provide biodegradable polymers great potential for industrial applications. In addition, it seems like the researches on tailored materials that are obtained by chemical modification of the existing materials or combination of different carriers in physical mixtures have a long way to go. Meanwhile, with the development of polymers and inorganic porous nanocarriers, nanotechnology is applied increasingly for the extended delivery of antibiotics. This review highlights the development of materials used in extended-release formulation and nanoparticles for antibiotic delivery. We also provide an overview of the antibiotic extended-release products that have provided clinical benefit or are undergoing the clinical trial.

show abstract

Section: Biodegradable Materialsmentioning

confidence: 99%

Recent advances in materials for extended-release antibiotic delivery system

et al. 2011

View full text Add to dashboard Cite

show abstract

“…With the development of pharmaceutics and nanotechnology, numerous novel kinds of polymers were synthesized or modified to meet the growing demands for pharmaceutical excipients. For examples, some polysaccharides especially modified celluloses were developed as sustained-release carriers in solid preparations aiming to achieve a smooth and long-acting release behavior [9,10]; Eudragit®, the brand name for a kind of commercially available polymethacrylate-based biomaterials, has been widely used in preparing enteric preparations [11]; PLA (poly (lactic acid)) and PLGA (poly (lactic-co-glycolic acid)) approved by FDA (Food and Drug Administration) in 1980s have been used extensively for preparing sustained-release injectable microspheres or nanoparticles [12,13]; some novel biopolymers were employed to achieve targeting preparations in nanoscale aiming to meet the "EPR effect" in tumor tissues [14,15]. Nowadays, the synthesized polymers are not merely used as excipients or framework material, but act as active pharmaceutical ingredients: RenaGel® (sevelamer hydrochloride), a hydrogel of cross-linked poly (allylamine hydrochloride), has been developed for the treatment of hyperphosphatemia [16,17].…”

Section: Introductionmentioning

confidence: 99%

Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?

Zhang¹,

Meng²,

Zhang³

2016

JPP

View full text Add to dashboard Cite

Non-absorbed macromolecular binders as sequestrants for phosphate ions offer an effective approach to treat hyperphosphatemia in ESRD (end-stage renal disease) patients. RenaGel® has been an example with remarkable success of a polymer synthesized to prevent the absorption of dietary phosphate for ESRD patients. Electrostatic interaction is the primary driving force for complexation of phosphate-based anions with these amino groups in the polymer backbone. Chitosan is a deacetylation product of chitin, which is the structural element in the exoskeleton of crustaceans and cell walls of fungi. The amino groups in the backbone give the phosphate binding ability to chitosan. This article has demonstrated that chitosan exhibited a phosphate binding effect indeed. Thus, it has potential applications in environmental management and wastewater treatment, as well as treatment of hyperphosphatemia patients.

show abstract

“…A clear example is the area of tissue engineering [3], for cell growth and differentiation are essential for producing artificial organs [4][5][6][7][8] and implants [9][10][11][12][13][14][15][16][17][18][19]. In drug delivery systems, surface coatings may be required for some types of release [20][21][22][23][24]. For the design of new pharmaceutical drugs, an important ingredient is the Advances in Colloid and Interface Science 207 (2014) [199][200][201][202][203][204][205][206][207][208][209][210][211][212][213][214][215] identification of the mode of action which is normally associated with the cell membranes (i.e.…”

Section: Introductionmentioning

confidence: 99%